No Data
Maximus Reports Weak Earnings, Joins Atkore, PDD Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Leerink Partners Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Announces Target Price $24
Centessa Pharmaceuticals Is Maintained at Buy by Guggenheim
Guggenheim Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Raises Target Price to $28
Morgan Stanley Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Raises Target Price to $27
BMO Capital Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Maintains Target Price $35